DeepMed Research

BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Castration Levels of Testosterone
Stage IV Prostate Adenocarcinoma AJCC v7
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
PSA Progression

Interventions: Drug: ESK981

First Posted Date: 2018-03-07

Last Posted Date: 2023-07-14

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 13

Registration Number: NCT03456804

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm

Phase 2

Completed

Conditions: Carcinoid Syndrome
Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm

Interventions: Other: Carbon C 11 Alpha-methyltryptophan
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography
Drug: Telotristat Etiprate

First Posted Date: 2018-03-05

Last Posted Date: 2025-04-10

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 4

Registration Number: NCT03453489

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo

Phase 2

Completed

Conditions: Stage II Bladder Urothelial Carcinoma AJCC v6 and v7
Stage IV Bladder Urothelial Carcinoma AJCC v7
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7

Interventions: Drug: Nivolumab
Radiation: Radiation

First Posted Date: 2018-02-05

Last Posted Date: 2023-08-04

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03421652

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Carcinoma Metastatic in the Bone
PSA Progression
Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Adenocarcinoma AJCC v7

Interventions: Biological: HER2Bi-Armed Activated T Cells
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2018-01-23

Last Posted Date: 2023-05-03

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 15

Registration Number: NCT03406858

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Phase 2

Active, not recruiting

Conditions: Recurrent Primary Amyloidosis

Interventions: Drug: Dexamethasone
Drug: Cyclophosphamide
Biological: Elotuzumab
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Pharmacological Study

First Posted Date: 2017-08-17

Last Posted Date: 2023-01-25

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 53

Registration Number: NCT03252600

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Levine Cancer Center, Charlotte, North Carolina, United States
🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 2 locations

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Extranodal Marginal Zone Lymphoma
Refractory Follicular Lymphoma
Stage IV Non-Hodgkin Lymphoma
Recurrent Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Waldenstrom Macroglobulinemia
Refractory Mantle Cell Lymphoma

Interventions: Drug: Selinexor

First Posted Date: 2017-05-10

Last Posted Date: 2025-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 69

Registration Number: NCT03147885

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 2

Completed

Conditions: Classical Hodgkin Lymphoma
Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma

Interventions: Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2016-07-06

Last Posted Date: 2025-02-17

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 28

Registration Number: NCT02824029

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Tennessee, Knoxville, Tennessee, United States
🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

and more 1 locations

Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

Not Applicable

Active, not recruiting

Conditions: Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma

Interventions: Drug: Dexamethasone
Device: Device for PET
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2016-06-30

Last Posted Date: 2023-05-06

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 6

Registration Number: NCT02819024

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

Low-Level Laser Therapy for Prevention of Oral Mucositis

Not Applicable

Completed

Conditions: Mucositis

Interventions: Device: Low Level Laser Therapy

First Posted Date: 2016-03-30

Last Posted Date: 2023-02-27

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 25

Registration Number: NCT02723604

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Biological: Aldesleukin
Biological: Antibody Therapy
Drug: Fluorouracil
Drug: Gemcitabine Hydrochloride
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Biological: Sargramostim

First Posted Date: 2015-12-03

Last Posted Date: 2023-05-15

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 2

Registration Number: NCT02620865

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy